1 |
Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b(+)/Gr-1(+)/D31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000. 96: 3838-3846.
|
2 |
Chatenoud L. Natural and induced T CD4+CD25+FOXP3+ regulatory T cells. Methods Mol Biol. 2011. 677: 3-13.
|
3 |
Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013. 10: 230-252.
DOI
|
4 |
den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol. 2004. 172: 6074-6079.
DOI
|
5 |
Fousteri G, Dave A, Juedes A, Juntti T, Morin B, Togher L, Farber DL, von Herrath M. Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure. PloS One. 2011. 6: e14502.
DOI
|
6 |
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009. 9: 162-174.
DOI
|
7 |
Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Muller M, Sexl V. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014. 124: 2370-2379.
DOI
|
8 |
Hadaschik B, Su Y, Huter E, Ge Y, Hohenfellner M, Beckhove P. Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. J Urol. 2012. 187: 1458-1465.
DOI
|
9 |
Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol. 2009. 182: 4217-4225.
DOI
|
10 |
Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005. 102: 9571-9576.
DOI
|
11 |
Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004. 172: 989-999.
DOI
|
12 |
Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med. 2005. 11: S54-62.
DOI
|
13 |
Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999. 5: 677-685.
DOI
|
14 |
Li Q, Pan PY, Gu P, Xu D, Chen SH. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. 2004. 64: 1130-1139.
DOI
|
15 |
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two sub-sets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999. 401: 708-712.
DOI
|
16 |
Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008. 111: 4233-4244.
DOI
|
17 |
Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010. 127: 759-767.
|
18 |
Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001. 411: 380-384.
DOI
|
19 |
Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 2013. 34: 33-40.
DOI
|
20 |
Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005. 115: 739-746.
DOI
|
21 |
Wesolowski R, Markowitz J, Carson WE, 3rd. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013. 1: 10.
DOI
|
22 |
Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 181: 5791-5802.
|
23 |
Zou W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2008. 5: 263-274.
|